His primary scientific interests are in Microbiology, Enterobacteriaceae, Escherichia coli, Ceftazidime and Cefotaxime. Jacques Sirot studies Cephalosporin which is a part of Microbiology. As a part of the same scientific family, he mostly works in the field of Cephalosporin, focusing on Klebsiella pneumoniae and, on occasion, Isoelectric point.
He has included themes like Antibacterial agent and Beta-lactamase in his Enterobacteriaceae study. His research in the fields of Shiga-like toxin overlaps with other disciplines such as STX2. His Ceftazidime study incorporates themes from Plasmid, Mutant and Enzyme.
The scientist’s investigation covers issues in Microbiology, Enterobacteriaceae, Ceftazidime, Escherichia coli and Antibacterial agent. His Microbiology research incorporates elements of Plasmid, Klebsiella pneumoniae and Imipenem. His Enterobacteriaceae study combines topics from a wide range of disciplines, such as Proteus mirabilis, Enterobacter aerogenes, Enzyme and Bacteria.
His Escherichia coli research includes themes of Amino acid, Ticarcillin, Diarrhea and Virulence. Jacques Sirot has researched Antibacterial agent in several fields, including Peptide sequence, Minimum inhibitory concentration, Mutant and Drug resistance. His research investigates the link between Cefotaxime and topics such as Aztreonam that cross with problems in Sulbactam.
His scientific interests lie mostly in Microbiology, Antibacterial agent, Enterobacteriaceae, Ceftazidime and Cefotaxime. Jacques Sirot combines subjects such as Proteus mirabilis, Escherichia coli and Plasmid with his study of Microbiology. His Antibacterial agent research is multidisciplinary, relying on both Molecular biology and Minimum inhibitory concentration.
His work deals with themes such as Beta-lactamase, Enterobacter aerogenes and Bacteria, which intersect with Enterobacteriaceae. His Ceftazidime study incorporates themes from Serratia marcescens, Mutant and Enzyme. The Cefotaxime study which covers Enterobacter cloacae that intersects with Citrobacter amalonaticus.
His primary areas of investigation include Microbiology, Cefotaxime, Enterobacteriaceae, Escherichia coli and Ceftazidime. Jacques Sirot combines subjects such as Pantoea agglomerans, Food microbiology and Arthritis with his study of Microbiology. His Cefotaxime research is multidisciplinary, relying on both Enterobacter cloacae and Antibacterial agent.
Jacques Sirot has researched Enterobacteriaceae in several fields, including Beta-lactamase, Enterobacter aerogenes and Bacteria. His work on Shiga-like toxin as part of general Escherichia coli study is frequently connected to STX2, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. His Ceftazidime research integrates issues from Enzyme assay and Enzyme.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel β-lactamase
D. Sirot;J. Sirot;R. Labia;A. Morand.
Journal of Antimicrobial Chemotherapy (1987)
Prevalence and characterization of Shiga toxin-producing Escherichia coli isolated from cattle, food and children during a one-year prospective study in France.
Nathalie Pradel;Valérie Livrelli;Christophe De Champs;Jean-Bernard Palcoux.
Journal of Clinical Microbiology (2000)
A novel CTX-M β-lactamase (CTX-M-8) in cefotaxime-resistant Enterobacteriaceae isolated in Brazil
R. Bonnet;J. L. M. Sampaio;R. Labia;C. De Champs.
Antimicrobial Agents and Chemotherapy (2000)
Novel cefotaximase (CTX-M-16) with increased catalytic efficiency due to substitution Asp-240-->Gly.
R. Bonnet;C. Dutour;J. L. M. Sampaio;C. Chanal.
Antimicrobial Agents and Chemotherapy (2001)
Klebsiella pneumoniae and other Enterobacteriaceae producing novel plasmid-mediated beta-lactamases markedly active against third-generation cephalosporins: epidemiologic studies.
J. Sirot;C. Chanal;A. Petit;D. Sirot.
Clinical Infectious Diseases (1988)
Non-O157:H7 Stx2-producing Escherichia coli strains associated with sporadic cases of hemolytic-uremic syndrome in adults.
R. Bonnet;B. Souweine;G. Gauthier;C. Rich.
Journal of Clinical Microbiology (1998)
Atomic resolution structures of CTX-M beta-lactamases: extended spectrum activities from increased mobility and decreased stability.
Yu Chen;Julien Delmas;Jacques Sirot;Brian Shoichet.
Journal of Molecular Biology (2005)
Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM beta-lactamases from clinical isolates of Escherichia coli.
C Henquell;C Chanal;D Sirot;R Labia.
Antimicrobial Agents and Chemotherapy (1995)
Effect of D240G substitution in a novel ESBL CTX-M-27
R. Bonnet;C. Recule;R. Baraduc;C. Chanal.
Journal of Antimicrobial Chemotherapy (2003)
Oral probiotic and prevention of Pseudomonas aeruginosa infections: a randomized, double-blind, placebo-controlled pilot study in intensive care unit patients
Christiane Forestier;Dominique Guelon;Valérie Cluytens;Thierry Gillart.
Critical Care (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: